Home Newsfeeds Wells Fargo Maintains Overweight on WalkMe, Raises Price Target to $13

Wells Fargo Maintains Overweight on WalkMe, Raises Price Target to $13

Wells Fargo analyst Michael Turrin maintains WalkMe (NASDAQ:WKME) with a Overweight and raises the price target from $12 to $13.

byBenzinga Newsdesk

February 16, 2023

1 minute read

Wells Fargo analyst Michael Turrin maintains WalkMe (NASDAQ:WKME) with a Overweight and raises the price target from $12 to $13.

Understanding Apple’s Position In Technology Hardware, Storage & Peripherals Industry Compared To Competitors

By Benzinga Insights

February 13, 12:00 PM

In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors…

AAPL

Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

By Benzinga Insights

January 25, 3:30 PM

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 4.47% on an annualized basis producing…

ABBV

Leap Therapeutics To Present Updated Data From Part A Of The DisTinGuish Study Of DKN-01 Plus Tislelizumab And Chemotherapy In Gastric Cancer Patients At The 2023 ASCO Annual Meeting

By Happy Mohamed

April 27, 6:57 AM

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new long-term follow-up data

LPTX

Li-Cycle Inks Long-Term Battery Recycling Relationship With VinES; Eyes Dedicated Spoke Plant In Vietnam

By Shivani Kumaresan

April 12, 9:45 AM

Li-Cycle Holdings Corp (NYSE:LICY) has signed an agreement with VinES Energy Solutions for long-term battery recycling. The financial terms were not disclosed. From…

LICY

Wells Fargo Maintains Overweight on WalkMe, Raises Price Target to $13

Related Posts

Understanding Apple’s Position In Technology Hardware, Storage & Peripherals Industry Compared To Competitors

Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

Leap Therapeutics To Present Updated Data From Part A Of The DisTinGuish Study Of DKN-01 Plus Tislelizumab And Chemotherapy In Gastric Cancer Patients At The 2023 ASCO Annual Meeting

Li-Cycle Inks Long-Term Battery Recycling Relationship With VinES; Eyes Dedicated Spoke Plant In Vietnam